Dasatinib

Dasatinib is a prescription tyrosine kinase inhibitor, not a supplement, and the longevity use discussed here is off-label and experimental. Be clear about the two separate evidence bases. The approved oncology use of dasatinib in chronic myeloid leukemia rests on a large phase III randomized trial with five-year follow-up in 519 patients (Cortes 2016, PMID: 27217448). The senolytic longevity hypothesis, in which intermittent dasatinib plus quercetin (D+Q) is used to clear senescent cells, rests on a much thinner base: rodent studies (Xu 2018, PMID: 29988130; Novais 2026, PMID: 41974671) plus four small human pilot trials totaling roughly 40 participants combined, none of them powered for efficacy, and the only randomized placebo-controlled human study to date reported feasibility and tolerability rather than benefit and found no meaningful between-group difference in physical or pulmonary function (Nambiar 2023, PMID: 36857968). The single most important human mechanistic result is that a three-day course reduced p16- and p21-expressing senescent cells in adipose tissue in nine adults with diabetic kidney disease (Hickson 2019, PMID: 31542391). The lifespan and healthspan claims that circulate about this combination come from mice, not people. Dasatinib carries real risks including pleural effusion, bleeding, myelosuppression, and QT prolongation, and it interacts sharply with CYP3A4 inhibitors and with acid-suppressing drugs. Quercetin alone is a widely available flavonoid supplement, but the senolytic protocols pair it with a chemotherapeutic agent, and that pairing is what changes the risk profile. Anyone considering this should be doing so under the direct supervision of a prescribing physician, ideally inside a registered clinical trial. Avelor does not provide a longevity dosing protocol for this drug.